This report is based on a press release statement from Eterna Therapeutics. For comprehensive financial analysis and real-time updates on ERNA's development progress, investors can access detailed metrics and expert insights through InvestingPro, including advanced valuation models and peer comparison tools essential for biotech investment decisions. For comprehensive financial analysis and real-time updates on ERNA's development progress, investors can access detailed metrics and expert insights through InvestingPro, including advanced valuation models and peer comparison tools essential for biotech investment decisions. The study, which involved a collaborative effort with MD Anderson Cancer Center, showcased a significant increase in T cell infiltration, tumor size reduction, and extended survival in an ovarian cancer mouse model.
The therapy, ERNA-101, uses induced pluripotent stem cells to create mesenchymal stem cells that secrete interleukins IL-7 and IL-15, which are known to enhance the immune system's ability to combat tumors. This innovative approach aims to convert "cold" tumors, characterized by low immune activity, into "hot" tumors, which have active immune environments. This could potentially improve therapeutic outcomes not only as a standalone treatment but also in conjunction with other therapies like CAR-T and CAR-NK cell therapies.
The study led by Michael Andreeff, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center, involved injecting mice with ID8 cells to develop an ovarian tumor model. The mice were then treated with ERNA-101. Compared to control groups, the ERNA-101 treated group exhibited a significant T cell presence in tumors, reduced tumor size, and a survival advantage. The safety of the therapy was also indicated by the lack of significant differences in body weight distribution between the treated and control groups.
Sanjeev Luther, CEO of Eterna Therapeutics, expressed optimism about the data, highlighting the potential of ERNA-101 to transform the treatment landscape for solid tumors, particularly ovarian cancer. Further research is anticipated to explore ERNA-101's full potential.
Eterna Therapeutics, a preclinical-stage company, is focusing on developing off-the-shelf synthetic iMSC therapies. The company's initial focus is on platinum-resistant ovarian cancer, and it is also investigating other potential treatments, including ERNA-102 for inflammatory/auto-immune disorders like rheumatoid arthritis.
This report is based on a press release statement from Eterna Therapeutics. For comprehensive financial analysis and real-time updates on ERNA's development progress, investors can access detailed metrics and expert insights through InvestingPro, including advanced valuation models and peer comparison tools essential for biotech investment decisions.
This report is based on a press release statement from Eterna Therapeutics.
In other recent news, Eterna Therapeutics Inc. is facing possible delisting from the Nasdaq Stock Market due to falling below the required minimum market value and bid price. Despite these challenges, the pharmaceutical company has been granted a 180-day period to regain compliance. Eterna Therapeutics has also experienced board changes with the resignation of Dorothy Clarke and the appointment of Dr. Elena Ratner. As part of its recent developments, Eterna Therapeutics announced a collaboration with The University of Texas MD Anderson Cancer Center to study the effects of its cell therapy ERNA-101 on ovarian and breast cancer models. The company also initiated a stock repurchase program and finalized a private placement stock sale, raising approximately $1.1 million for general working capital. In addition, Eterna Therapeutics entered into an exclusive license and collaboration agreement with Factor Bioscience Limited. Despite these developments, the company's listing status remains unchanged for now.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.